BRC
TVRD

Bell Rock Capital’s Tvardi Therapeutics TVRD Stock Holding History

Bell Rock Capital’s Portfolio TVRD Stock Details TVRD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-33
Closed -$24K – 468
2019
Q1 		$24K Hold
33
– – 0.01% 285
2018
Q4 		$16K Hold
33
– – 0.01% 323
2018
Q3 		$29K Hold
33
– – 0.01% 281
2018
Q2 		$23K Sell
33
-2
-6% -$1.02K 0.01% 318
2018
Q1 		$16K Buy
35
+7
+25% +$3.4K 0.01% 347
2017
Q4 		$12K Buy
28
+10
+56% +$4.56K 0.01% 347
2017
Q3 		$9K Hold
18
– – 0.01% 347
2017
Q2 		$10K Buy
+18
New +$11.4K 0.01% 342

Other funds holding TVRD

RCP
Rho Capital Partners New York $20.4M AUM
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
First Manhattan
First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
C
Chescapmanager Baltimore, Maryland $1.12B AUM 67.49% 1-Year Est. Return
EMG
ETF Managers Group Summit, New Jersey $3.1B AUM 17.12% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
DGI
Disciplined Growth Investors Minneapolis, Minnesota $4.89B AUM 33.85% 1-Year Est. Return

Bell Rock Capital's TVRD Position: Q2 2019 in Review

Bell Rock Capital sold out of Tvardi Therapeutics (TVRD) in Q2 2019, closing a stake of 33 shares — an estimated $24K sold.

Bell Rock Capital first reported a position in TVRD in Q2 2017 and held it in 8 quarters. The position peaked at $29K in Q3 2018. 126 funds tracked by Wall St. Rank hold TVRD as of Q2 2019.

  • Bell Rock Capital reported no remaining Tvardi Therapeutics position as of Q2 2019 after selling out during the quarter.
  • Bell Rock Capital sold 33 Tvardi Therapeutics shares in Q2 2019, an estimated $24K.
  • Bell Rock Capital first reported a position in Tvardi Therapeutics in Q2 2017 and held it in 8 quarters.
  • Bell Rock Capital's Tvardi Therapeutics position peaked at $29K in Q3 2018.
  • 126 funds tracked by Wall St. Rank held Tvardi Therapeutics as of Q2 2019.

Based on Bell Rock Capital's 13F filing for Q2 2019, filed 31 Jul 2019.